This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr Reddy Laboratories Ltd (RDY)

NYSE: Health Care

$49.73 -0.02 | -0.04%
11/25/15 - 3:59:45 PM ET (BATS BZX Real-time Price)
  • Prev Close: 49.75
  • Day's Open: 49.70
  • Volume: 449.63K
  • Avg Vol: 492.00K
  • Shares Outstanding: 170.59M
  • Mkt Cap: 8.66B
  • Div: $0.29
  • Div Yield: 0.60%
  • P/E: 24.16
  • EPS: 2.08
RDY Day's Range
RDY 52 Week Range
RDY Business Summary
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products.View RDY key stats
Dr Reddy Laboratories Ltd - RDY - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Dr Reddy Laboratories Ltd as a Buy with a ratings score of B+.
Report Snippet: We rate DR REDDY'S LABORATORIES LTD (RDY) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.
Rating: 4.0 out of 5, 'B+' Buy.
You can view the full analysis from the report here:
RDY Rating Report
RDY Performance as of Prev. Close
RDY EPS Performance
1-Yr Ago
2-Yrs Ago
3-Yrs Ago
RDY Percentage in these ETFs
RDY News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

RDY Dr Reddy Laboratories Ltd

Chart of RDY

Analysts Ratings for RDY

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0

RDY Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs